The CRO's work with La Jolla Institute for Immunology, centered on a unique mouse model, is intended to increase understanding of how the COVID-19 virus operates.
ImmunoScape plans to use the investor funds to grow its Asia presence, expand into the US, and to further develop its Deep Immunomics platform technology.
The research models and services provider has acquired a company that specializes in tissue collections, and hematology, and immunology cell isolations to help meet its ‘ever-increasing’ client needs.
Aetion aims to advance the adoption of and standards for real-world evidence backed by a strategic investment from several global biopharma and health care companies.
The PE firm Ampersand Capital Partners has acquired Pacific Biomarkers and is merging the CRO with Neomed-Labs to streamline clinical immunology development.
Clinical trials of cancer vaccines should enrol patients with no evidence of residual disease, according to FDA guidance, but this will increase development times compared to cytotoxic agents.
MDS Pharma Services has expanded its portfolio of bioanalytical
testing services with the addition of electrochemiluminescent assay
(ECLA) capability, used to test biological samples from clinical
research participants.
A group of scientists are using real-world experimental data to
generate a virtual model of the human immune system, which could
then be used in drug design.
Guava Technologies aim to simplify antibody screening with its new
range of quantitative bead-based kits designed to quantify either
mouse or human IgG antibody (Immunoglobulin G) during hybridoma
screening.
Scientists have found that certain T-cell stimulation could help
improve treatment of autoimmune disease and cancer, which could be
significant for developing new drug treatments to help patients
with autoimmune diseases such as rheumatoid...
